Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TNGX
Tango Therapeutics, Inc.
Healthcare | Biotechnology
No licensed closing price on file for TNGX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
EPS (TTM)$-0.85
Tango Therapeutics, Inc. (NASDAQ: TNGX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 00:35 UTC.
Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
2026-08-06Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersBarbara Weber'sEstimatedSEC 8-K →
2026-06-23Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2026-05-08Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
Tango Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as TNGX.
When did TNGX last file with the SEC?
Tango Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.
Where does this data come from?
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 00:35 UTC. This page is also available as JSON at /api/data?ticker=TNGX and is emitted with FAQPage structured data for machine reading.
For you
Charts, 10-year financials, peer comparison, screening and portfolio tracking for TNGX and 5,000+ tickers.
Oxford Ledge
Search